From Bench to Bedside: Immunotherapy for Prostate Cancer

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tse, Brian Wan-Chi, Jovanovic, Lidija, Nelson, Colleen Coyne, de Souza, Paul, Power, Carl Andrew, Russell, Pamela Joan
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi Publishing Corporation 2014
Assuntos:
Review Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4168152/
https://ncbi.nlm.nih.gov/pubmed/25276838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/981434
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares